Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Lokhorst HM et al. N Engl J Med. 2015 Aug 26. [Epub ahead of print].
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.
Kumar SK et al. Blood Cancer J. 2015 Aug 14;4:e338. doi: 10.1038/bcj.2015.60.
Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity.
Ganai SA. Curr Top Med Chem. 2015 Aug 13. [Epub ahead of print].
Monoclonal antibodies in the treatment of multiple myeloma: Current status and future perspectives.
Lonial S et al. Leukemia. 2015 Aug 12. doi: 10.1038/leu.2015.223. [Epub ahead of print].
Panobinostat (Farydak) for multiple myeloma.
[No authors listed]. Med Lett Drugs Ther. 2015 Aug 17;57(1475):e118-9.
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ et al. Blood Cancer J. 2015 Aug 7;5:e334. doi: 10.1038/bcj.2015.62.
Ibrutinib: from bench side to clinical implications.
Grisafi D et al. Med Oncol. 2015 Sep;32(9):669. doi: 10.1007/s12032-015-0669-9. Epub 2015 Jul 30.
Monoclonal Antibodies in Multiple Myeloma Come of Age.
Raje N et al. N Engl J Med. 2015 Aug 26. [Epub ahead of print].